Hansa Biopharma
Tracked across 2 events · 14 articles · First seen Feb 11, 2026 · Last active Mar 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Hansa Biopharma reported strong Q4 2025 and full-year financial results, with significant increases in IDEFIRIX product sales and total revenue. The company also submitted a Biologics License Application (BLA) for imlifidase to the U.S. Food and Drug Administration (FDA) and is advancing its next-generation enzyme HNSA-5487 for Guillain-Barré syndrome. These developments indicate positive momentum for Hansa Biopharma's stock price and future growth.
Feb 11, 2026 · 7 articles
Regulatory
Hansa Biopharma is the developer of imlifidase, and the acceptance of its Biologics License Application by the United States===Food and Drug Administration marks an important milestone for the company. This development brings Hansa Biopharma closer to potentially offering a transformative therapy option for kidney transplant patients.
Mar 04, 2026 · 7 articles
NEWSDESK
Track Hansa Biopharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard